Developing Countries: Coronavirus

(asked on 6th January 2021) - View Source

Question to the Foreign, Commonwealth & Development Office:

To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what estimate his Department has made of the average cost of a Oxford AstraZeneca covid-19 vaccination procured by COVAX under the advance market commitment agreement.


Answered by
Wendy Morton Portrait
Wendy Morton
This question was answered on 11th January 2021

The UK welcomes AstraZeneca's commitment to non-profit equitable access and encourages other manufacturers to do the same during the pandemic. COVAX has an advance purchase agreement with AstraZeneca for 170 million doses of the AstraZeneca/Oxford candidate at non-profit pricing. Gavi and Unicef will publish procurement prices in due course. This is in addition to an existing agreement with the Serum Institute of India (SII) for 200 million doses - with options for up to 900 million doses more - of either the AstraZeneca/Oxford or Novavax vaccines (the latter is yet to complete phase 3 trials). The agreement with SII will see any combination of these vaccines be available at a price no greater than US$3 a dose.

The UK is committed to rapid equitable access to safe and effective vaccines at affordable prices. The UK has committed up to £548 million to the COVAX Advance Market Commitment (AMC), an international initiative that will support global equitable access to vaccines in up to 92 low and middle-income countries. The AMC will supply 1 billion doses in 2021, vaccinating up to 500 million people.

Reticulating Splines